Literature DB >> 19155509

Novel Chlamydia muridarum T cell antigens induce protective immunity against lung and genital tract infection in murine models.

Hong Yu1, Xiaozhou Jiang, Caixia Shen, Karuna P Karunakaran, Robert C Brunham.   

Abstract

Using a combination of affinity chromatography and tandem mass spectrometry, we recently identified 8 MHC class II (I-A(b)) -bound Chlamydia peptides eluted from dendritic cells (DCs) infected with Chlamydia muridarum. In this study we cloned and purified the source proteins that contained each of these peptides and determined that three of the eight peptide/protein Ags were immunodominant (PmpG-1, RplF, and PmpE/F-2) as identified by IFN-gamma ELISPOT assay using splenocytes from C57BL/6 mice recovered from C. muridarum infection. To evaluate whether the three immunodominant Chlamydia protein Ags were also able to protect mice against Chlamydia infection in vivo, we adoptively transferred LPS-matured DCs transfected ex vivo with the cationic liposome DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate) and individual PmpG-1(25-500aa), RplF, or PmpE/F-2 (25-575 aa) proteins. The results showed that the transfected Chlamydia proteins were efficiently delivered intracellularly into DCs. Mice vaccinated with DCs transfected with individual Chlamydia protein PmpG-1(25-500), RplF, or PmpE/F-2(25-575) exhibited significant resistance to challenge infection as indicated by reduction in the median Chlamydia inclusion forming units in both the lung and genital tract models. The major outer membrane protein was used as a reference Ag but conferred significant protection only in the genital tract model. Overall, vaccination with DCs transfected with PmpG-1(25-500) exhibited the greatest degree of protective immunity among the four Chlamydia Ags tested. This study demonstrates that T cell peptide Ags identified by immunoproteomics can be successfully exploited as T cell protein-based subunit vaccines and that PmpG-1(25-500) protein may be a suitable vaccine candidate for further evaluation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19155509      PMCID: PMC2637473          DOI: 10.4049/jimmunol.182.3.1602

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

1.  NK T cell activation promotes Chlamydia trachomatis infection in vivo.

Authors:  Laura Bilenki; Shuhe Wang; Jie Yang; Yijun Fan; Antony George Joyee; Xi Yang
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

2.  Immunoreactivity and differential developmental expression of known and putative Chlamydia trachomatis membrane proteins for biologically variant serovars representing distinct disease groups.

Authors:  João P Gomes; Ru-ching Hsia; Sally Mead; Maria J Borrego; Deborah Dean
Journal:  Microbes Infect       Date:  2005-02-24       Impact factor: 2.700

Review 3.  Conquering sexually transmitted diseases.

Authors:  Michael N Starnbach; Nadia R Roan
Journal:  Nat Rev Immunol       Date:  2008-02-29       Impact factor: 53.106

4.  Comparative genomic analysis of Chlamydia trachomatis oculotropic and genitotropic strains.

Authors:  John H Carlson; Stephen F Porcella; Grant McClarty; Harlan D Caldwell
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

Review 5.  Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine.

Authors:  Robert C Brunham; José Rey-Ladino
Journal:  Nat Rev Immunol       Date:  2005-02       Impact factor: 53.106

6.  Polymorphisms in the nine polymorphic membrane proteins of Chlamydia trachomatis across all serovars: evidence for serovar Da recombination and correlation with tissue tropism.

Authors:  João P Gomes; Alexandra Nunes; William J Bruno; Maria J Borrego; Carlos Florindo; Deborah Dean
Journal:  J Bacteriol       Date:  2006-01       Impact factor: 3.490

7.  The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection.

Authors:  Robert C Brunham; Babak Pourbohloul; Sunny Mak; Rick White; Michael L Rekart
Journal:  J Infect Dis       Date:  2005-10-10       Impact factor: 5.226

8.  Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection.

Authors:  Weidang Li; Ashlesh K Murthy; M Neal Guentzel; J Seshu; Thomas G Forsthuber; Guangming Zhong; Bernard P Arulanandam
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

9.  Immunoproteomic discovery of novel T cell antigens from the obligate intracellular pathogen Chlamydia.

Authors:  Karuna P Karunakaran; Jose Rey-Ladino; Nikolay Stoynov; Kyra Berg; Caixia Shen; Xiaozhou Jiang; Brent R Gabel; Hong Yu; Leonard J Foster; Robert C Brunham
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

10.  Comparative expression profiling of the Chlamydia trachomatis pmp gene family for clinical and reference strains.

Authors:  Alexandra Nunes; João P Gomes; Sally Mead; Carlos Florindo; Helena Correia; Maria J Borrego; Deborah Dean
Journal:  PLoS One       Date:  2007-09-12       Impact factor: 3.240

View more
  31 in total

Review 1.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  Vaccination with major outer membrane protein proteosomes elicits protection in mice against a Chlamydia respiratory challenge.

Authors:  Delia F Tifrea; Sukumar Pal; Deana N Toussi; Paola Massari; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-08-30       Impact factor: 2.700

3.  Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge.

Authors:  Nina Dieu Nhien Tran Nguyen; Anja W Olsen; Emma Lorenzen; Peter Andersen; Malene Hvid; Frank Follmann; Jes Dietrich
Journal:  NPJ Vaccines       Date:  2020-01-23       Impact factor: 7.344

4.  Identification of Chlamydia trachomatis Antigens Recognized by T Cells From Highly Exposed Women Who Limit or Resist Genital Tract Infection.

Authors:  Ali N Russell; Xiaojing Zheng; Catherine M O'Connell; Harold C Wiesenfeld; Sharon L Hillier; Brandie D Taylor; Michelle D Picard; Jessica B Flechtner; Wujuan Zhong; Lauren C Frazer; Toni Darville
Journal:  J Infect Dis       Date:  2016-10-12       Impact factor: 5.226

Review 5.  Development of a Chlamydia trachomatis T cell Vaccine.

Authors:  Karuna P Karunakaran; Hong Yu; Leonard J Foster; Robert C Brunham
Journal:  Hum Vaccin       Date:  2010-08-01

6.  Frequency of Chlamydia trachomatis-specific T cell interferon-γ and interleukin-17 responses in CD4-enriched peripheral blood mononuclear cells of sexually active adolescent females.

Authors:  Romina Barral; Ruchi Desai; Xiaojing Zheng; Lauren C Frazer; Gina S Sucato; Catherine L Haggerty; Catherine M O'Connell; Matthew A Zurenski; Toni Darville
Journal:  J Reprod Immunol       Date:  2014-02-01       Impact factor: 4.054

7.  Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection.

Authors:  Norma Olivares-Zavaleta; William Whitmire; Donald Gardner; Harlan D Caldwell
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

8.  Protection against Chlamydia promoted by a subunit vaccine (CTH1) compared with a primary intranasal infection in a mouse genital challenge model.

Authors:  Anja Weinreich Olsen; Michael Theisen; Dennis Christensen; Frank Follmann; Peter Andersen
Journal:  PLoS One       Date:  2010-05-21       Impact factor: 3.240

9.  Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice.

Authors:  Hong Yu; Karuna P Karunakaran; Xiaozhou Jiang; Robert C Brunham
Journal:  Vaccine       Date:  2014-06-30       Impact factor: 3.641

10.  Suppression of Chlamydial Pathogenicity by Nonspecific CD8+ T Lymphocytes.

Authors:  Lingxiang Xie; Conghui He; Jianlin Chen; Lingli Tang; Zhiguang Zhou; Guangming Zhong
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.